Cellect Biotechnology (NASDAQ:APOP) released its quarterly earnings data on Thursday. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.14, Fidelity Earnings reports.
Shares of Cellect Biotechnology traded up $0.18, reaching $7.18, during mid-day trading on Friday, according to MarketBeat Ratings. 70 shares of the company’s stock were exchanged, compared to its average volume of 81,660. Cellect Biotechnology has a 52-week low of $7.11 and a 52-week high of $7.11.
Separately, Zacks Investment Research raised shares of Cellect Biotechnology from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Tuesday, March 20th.
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.